Alex McHenry (COO) wrote it I believe. As JoesyWales said, please get in touch with him and make your points (perhaps a litIf anytle less sharply). I've already flagged similar points to him, but if you are a medical specialist he's more apt to listen to you.
If anyone has constructive advice for them I think it will be welcomed. Personally I think the medical data could have been more clearly explained and distinctly separate from the Quadriplegic stories, which themselves required a little more clarification. The title was misleading in that this is a wider nerve regeneration study and the subset of Quadriplegic patients a wonderful story within the results that should have been more clearly distinguished as such.
Ann: CelGro Nerve Regeneration Results in Quadriplegic Patients, page-250
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.5¢ |
Change
-0.015(2.34%) |
Mkt cap ! $149.4M | |||
| Open | High | Low | Value | Volume |
| 64.5¢ | 64.5¢ | 62.0¢ | $124.1K | 195.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12045 | 62.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 20258 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |